The extracellular matrix (ECM)-degrading nanoagonist (dNAc) with a second near-infrared (NIR-II) light-controlled system also activates STING-dependent type 1 IFN release during mild photothermal-augmented chemodynamic-immunotherapy in a mouse model of breast cancer [215]. This evidence concerns the gene STING1 and breast cancer.